3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Acrocephalosyndactylia
5
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Myeloproliferative Disorders
2
Stomach Neoplasms
1
Recurrence
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Multiple Myeloma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Eosinophilia
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Malignancies
1
Interventions
Dexamethasone
43
Cyclophosphamide
38
fludarabine phosphate
27
Cytarabine
26
Rituximab
24
Methotrexate
21
Lenalidomide
21
Bortezomib
21
Calcium Dobesilate
20
fludarabine
19
Peripheral Blood Stem Cell Transplantation
19
Whole-Body Irradiation
16
Mycophenolic Acid
16
pembrolizumab
15
Gemcitabine
15
Etoposide
15
pomalidomide
14
Melphalan
14
Vincristine
13
Filgrastim
13
Busulfan
13
Tacrolimus
12
Cyclosporine
12
Carboplatin
12
Paclitaxel
11
carfilzomib
10
durvalumab
9
Doxorubicin
9
Cetuximab
9
Brentuximab Vedotin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Recurrence
×
pemigatinib
×
Clear all
NCT05253807
2025-08-05
FIGHT-210
Incyte Corporation
Phase 2
Completed
8 enrolled
13 charts